Press Releases
Filters
November 16, 2021
Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
November 11, 2021
Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities
October 20, 2021
Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary
October 13, 2021
Viatris Inc. to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
July 28, 2021
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
July 8, 2021
Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021
Displaying 71 - 80 of 98